Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of ...

If you have been diagnosed with MDS, you may be able to receive a stem cell transplant, also called a bone marrow transplant. It has the potential to cure MDS. Learn more about our stem cell ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes ...

Request an Appointment Fred Hutch: A Leader in MDS Treatment Fred Hutch is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation for the diagnosis and treatment of MDS. Our ...

Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS ...

Several other diseases can be confused with MDS, including: aplastic anemia certain leukemias, including acute leukemia and large granular lymphocytic leukemia HIV infection an overactive immune ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, has announced the identification of the final patient for its BEXMAB Phase II ...

This is the third indication for Reblozyl (luspatercept), which is already used to treat anaemia in patients with rare blood disorder beta thalassaemia and as a second-line therapy for MDS ...